MD4348B1 - Combinaţie între 4-{3-[cis-hexahidrociclopenta[c]pirol-2(1H)-il]propoxi}benzamidă şi un antagonist al receptorului NMDA, şi compoziţii farmaceutice care o conţin - Google Patents

Combinaţie între 4-{3-[cis-hexahidrociclopenta[c]pirol-2(1H)-il]propoxi}benzamidă şi un antagonist al receptorului NMDA, şi compoziţii farmaceutice care o conţin

Info

Publication number
MD4348B1
MD4348B1 MDA20120119A MD20120119A MD4348B1 MD 4348 B1 MD4348 B1 MD 4348B1 MD A20120119 A MDA20120119 A MD A20120119A MD 20120119 A MD20120119 A MD 20120119A MD 4348 B1 MD4348 B1 MD 4348B1
Authority
MD
Moldova
Prior art keywords
receptor antagonist
hexahydrocyclopenta
pyrrol
benzamide
propoxy
Prior art date
Application number
MDA20120119A
Other languages
English (en)
Russian (ru)
Inventor
Орор СОР
Карен ТРОКМЕ-ТИБЬЕРЖ
Аннетт МЕРДЕ
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47682151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4348(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of MD4348B1 publication Critical patent/MD4348B1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Prezenta invenţie se referă la o combinaţie nouă între 4-{3-[cis-hexahidrociclopenta[c]pirol-2(1H)-il]propoxi}benzamidă cu formula (I):sau o sare de adiţie a acesteia cu un acid sau o bază acceptabile farmaceutic, şi un antagonist al receptorilor glutamatergici NMDA (N-metil-D-aspartat), şi anume memantina, pentru obţinerea compoziţiilor farmaceutice cu scopul utilizării lor în tratamentul tulburărilor cognitive asociate cu îmbătrânirea cerebrală şi bolile neurodegenerative.În special pentru tratament sunt vizate tulburările cognitive asociate cu boala Alzheimer.Acţiunea antagonistului receptorilor glutamatergici NMDA este sporită de 4-{3-[cis-hexahidrociclopenta[c]pirol-2(1H)-il]propoxi}benzamidă sau de sărurile de adiţie ale acesteia cu un acid sau o bază acceptabile farmaceutic. Coadministrarea acestor compuşi permite de a micşora dozele terapeutice ale memantinei şi a îmbunătăţi activitatea cognitivă a pacienţilor fără a spori reacţiile adverse ale antagonistului receptorilor NMDA.
MDA20120119A 2011-12-09 2012-12-03 Combinaţie între 4-{3-[cis-hexahidrociclopenta[c]pirol-2(1H)-il]propoxi}benzamidă şi un antagonist al receptorului NMDA, şi compoziţii farmaceutice care o conţin MD4348B1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568831P 2011-12-09 2011-12-09
FR1103777A FR2983732B1 (fr) 2011-12-09 2011-12-09 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
MD4348B1 true MD4348B1 (ro) 2015-05-31

Family

ID=47682151

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20120119A MD4348B1 (ro) 2011-12-09 2012-12-03 Combinaţie între 4-{3-[cis-hexahidrociclopenta[c]pirol-2(1H)-il]propoxi}benzamidă şi un antagonist al receptorului NMDA, şi compoziţii farmaceutice care o conţin

Country Status (27)

Country Link
US (2) US8921409B2 (ro)
EP (1) EP2601942A1 (ro)
JP (1) JP5591310B2 (ro)
KR (1) KR101489670B1 (ro)
CN (1) CN103157111B (ro)
AP (1) AP3225A (ro)
AR (1) AR089112A1 (ro)
AU (1) AU2012258339A1 (ro)
BR (1) BR102012031031A2 (ro)
CA (1) CA2798549A1 (ro)
CL (1) CL2012003437A1 (ro)
CO (2) CO6660080A1 (ro)
CR (1) CR20120608A (ro)
EA (1) EA201201530A1 (ro)
EC (1) ECSP12012329A (ro)
FR (1) FR2983732B1 (ro)
GT (1) GT201200329A (ro)
MA (1) MA34867B1 (ro)
MD (1) MD4348B1 (ro)
MX (1) MX2012014184A (ro)
NI (1) NI201200178A (ro)
PE (1) PE20130813A1 (ro)
SG (1) SG191494A1 (ro)
TN (1) TN2012000563A1 (ro)
TW (1) TWI457123B (ro)
UY (1) UY34475A (ro)
WO (1) WO2013083887A1 (ro)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3003466B1 (fr) * 2013-03-22 2015-08-07 Servier Lab Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques
KR101484405B1 (ko) * 2013-08-14 2015-01-19 서울대학교산학협력단 Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물
GB201509134D0 (en) * 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
CN116687906A (zh) * 2015-07-22 2023-09-05 阿纳韦克斯生命科学公司 ANAVEX2-73的对映体及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
WO2005084655A1 (en) * 2004-03-03 2005-09-15 Merz Pharma Gmbh & Co. Kgaa 1-aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease
WO2005089747A1 (fr) * 2004-02-20 2005-09-29 Les Laboratoires Servier Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2010043787A1 (fr) * 2008-10-16 2010-04-22 Les Laboratoires Servier Utilisation du 4-(3-[hexahydrocyclopenta[c]pyrrol-i(ih)- yl]propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
WO2011070251A1 (fr) * 2009-12-09 2011-06-16 Les Laboratoires Servier Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1509232T1 (sl) * 2002-05-31 2009-04-30 Lundbeck & Co As H Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
AU2004251636B2 (en) * 2003-05-27 2006-11-09 Merz Pharma Gmbh & Co. Kgaa Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
US7432280B2 (en) * 2003-06-20 2008-10-07 Eli Lilly And Company 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
EP1740172A4 (en) * 2004-03-19 2007-10-10 Axonyx Inc ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
FR2937119B1 (fr) 2008-10-15 2010-12-17 Air Liquide Procede de production d'energie et capture de co2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
WO2005089747A1 (fr) * 2004-02-20 2005-09-29 Les Laboratoires Servier Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005084655A1 (en) * 2004-03-03 2005-09-15 Merz Pharma Gmbh & Co. Kgaa 1-aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer’s disease
WO2010043787A1 (fr) * 2008-10-16 2010-04-22 Les Laboratoires Servier Utilisation du 4-(3-[hexahydrocyclopenta[c]pyrrol-i(ih)- yl]propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
WO2011070251A1 (fr) * 2009-12-09 2011-06-16 Les Laboratoires Servier Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
5872. Memantine. THE MERCK INDEX, Twelth Edition, MERCK & CO., Inc., N.Y., 1996. pag. 993-994 *
NMDA receptor anthagonist, ( 29.11.2011 version). WikipediA, The Free Encyclopedia. Vizitat la 2014.12.01, url: https://en.wikipedia.org/wiki/NMDA_receptor_antagonist vezi "Potential for treatment of exitotoxicity" *

Also Published As

Publication number Publication date
TWI457123B (zh) 2014-10-21
WO2013083887A8 (fr) 2013-08-08
CO6660080A1 (es) 2013-04-30
MX2012014184A (es) 2013-06-18
PE20130813A1 (es) 2013-07-28
BR102012031031A2 (pt) 2013-10-29
TW201334777A (zh) 2013-09-01
AP2012006607A0 (en) 2012-12-31
WO2013083887A1 (fr) 2013-06-13
KR20130065602A (ko) 2013-06-19
US20130150421A1 (en) 2013-06-13
CL2012003437A1 (es) 2014-01-24
CN103157111B (zh) 2015-02-11
CO6690116A1 (es) 2013-06-17
ECSP12012329A (es) 2013-01-31
CR20120608A (es) 2014-03-05
FR2983732A1 (fr) 2013-06-14
SG191494A1 (en) 2013-07-31
FR2983732B1 (fr) 2013-11-22
GT201200329A (es) 2014-03-14
UY34475A (es) 2013-07-31
US8921409B2 (en) 2014-12-30
US20150080448A1 (en) 2015-03-19
NZ604084A (en) 2014-07-25
MA34867B1 (fr) 2014-02-01
JP2013121956A (ja) 2013-06-20
JP5591310B2 (ja) 2014-09-17
KR101489670B1 (ko) 2015-02-04
CN103157111A (zh) 2013-06-19
AU2012258339A1 (en) 2013-06-27
NI201200178A (es) 2013-05-13
EP2601942A1 (fr) 2013-06-12
TN2012000563A1 (fr) 2014-04-01
AP3225A (en) 2015-04-30
CA2798549A1 (fr) 2013-06-09
EA201201530A1 (ru) 2013-07-30
AR089112A1 (es) 2014-07-30

Similar Documents

Publication Publication Date Title
CY1124882T1 (el) Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
TN2013000293A1 (en) Derivatives of azaindazole or diazaindazole type as medicament
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
CY1119420T1 (el) Νεες θεραπευτικες προσεγγισεις για θεραπεια ασθενειας parkinson
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
CY1119597T1 (el) Συνθεσεις και μεθοδοι για υπερκεραση αντοχης σε τραμαδολη
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2011011273A (es) Derivados de isoxazol-pirazol.
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
IN2014DN05869A (ro)
RU2013153140A (ru) Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
JP2013518914A5 (ro)
UA117154C2 (uk) Антагоністи s1p3
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MD4348B1 (ro) Combinaţie între 4-{3-[cis-hexahidrociclopenta[c]pirol-2(1H)-il]propoxi}benzamidă şi un antagonist al receptorului NMDA, şi compoziţii farmaceutice care o conţin
EA201290694A1 (ru) Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
CY1116518T1 (el) Παραγωγο 1,2,4-τριαζολονης
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MY170152A (en) Ethynyl derivative as modulators of mglur5 receptor activity
SI2729474T1 (en) (TIENO (2,3-b) (1,5) BENZOXAZEPIN-4-YL) PIPERAZINE-1-IL COMPOUNDS AS TWO ACTIVE H1 INVERTIVE AGENTS / 5-HT2A ANTAGONISTS

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)